Apollomics Inc Class A Ordinary Shares

Yahoo Finance • last month

Apollomics Announces Settlement of Cayman Litigation

FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement” or the “Agreement”) with TWVC Goldlink... Full story

Yahoo Finance • last month

Apollomics Announces Changes to its Board of Directors and Composition of Committees

FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today announced the following update regarding chang... Full story

Yahoo Finance • 2 months ago

Apollomics 宣布听证会取消后继续在 Nasdaq 股票市场上市

加利福尼亚州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq 代码：APLM，以下简称 “Apollomics” 或“公司”) 是一家总部位于加利福尼亚州的晚期临床阶段生物制药公司，致力于开发多种针对难治性和耐药性癌症的候选肿瘤药物。此前，该公司曾宣布已提交申请，拟就 Nasdaq Stock Market, LLC (以下简称“Nasdaq”) 上市资格部门（以下简称“部门”）此前发出的退市... Full story

Yahoo Finance • 2 months ago

聽證會取消後，Apollomics 宣佈繼續於 The Nasdaq Stock Market 維持其上市地位

加州福斯特城, Oct. 17, 2025 (GLOBE NEWSWIRE) -- 總部設於加州的 Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「公司」) 是一家晚期臨床生物製藥公司，開發多種腫瘤候選藥物對抗難以根治及對治療有抗藥性的癌症。該公司較早時宣佈已向 The Nasdaq Stock Market, LLC (簡稱「Nasdaq」) 之上市資格人員（簡稱「上市資格人員」）提交申請，對先前收到之除牌通知提出上訴，並要... Full story

Yahoo Finance • 2 months ago

Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation

FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to addre... Full story

Yahoo Finance • 2 months ago

Apollomics, Inc. 公司运营持续状态更新

加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq：APLM) (简称“Apollomics”或“公司”) 今日发布以下公司运营更新。 Apollomics 是一家临床阶段的生物技术公司，致力于推进创新肿瘤疗法，以改变那些治疗选择稀少或毫无选择的患者的治疗格局。公司目前在 11 个项目中拥有 9 款在研候选药物，其中 6 款处于临床开发阶段，专注研发用于治疗肺癌、脑癌及其他实体瘤等具有挑战... Full story

Yahoo Finance • 2 months ago

Apollomics, Inc. 公司營運持續性最新消息

加州福特斯城, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (「Apollomics」或「該公司」) 今日發佈了以下公司營運的最新消息。 Apollomics 是一家臨床階段生物科技公司，致力推進創新腫瘤療法，為療選擇不多或別無選擇的患者改變治療格局。該公司的產品線擁有九種候選產品，涵蓋 11 項計劃，當中包括六項處於臨床開發階段的計劃。該公司專注於對抗肺癌、腦癌及其他實體腫瘤等最棘... Full story

Yahoo Finance • 2 months ago

Nasdaq Resumes Trading in Apollomics Inc.

NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq: APLMW) at 9:00 a.m. and 9:05 a.m. East... Full story

Yahoo Finance • 2 months ago

Apollomics, Inc. Company Operational Continuity Update

FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update. Apollomics is a clinical-stage biotechnology company advanc... Full story

Yahoo Finance • 3 months ago

Nasdaq Halts Apollomics Inc., Ltd.

NEW YORK, Sept. 17, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading was halted on September 17, 2025 in Apollomics Inc., Ltd. at 14:37:17 Eastern Time for additional information requested from the... Full story

Yahoo Finance • 9 months ago

Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress

Strategic collaboration with LaunXP for the development of vebreltinib in combination with an EGFR inhibitor (“EGFRi”) to bring in $10 million upfront payment and expand dataset to combination therapyNew interim data for the vebreltinib de... Full story

Yahoo Finance • 9 months ago

Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib

LaunXP receives exclusive development and commercialization rights for vebreltinib in combination with an EGFR inhibitor in Asia (excluding mainland China, Hong Kong and Macau) for the treatment of non-small cell lung cancer (“NSCLC”)Apoll... Full story

Yahoo Finance • 2 years ago

Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)

FOSTER CITY, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatme... Full story

Yahoo Finance • 2 years ago

Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer

Apollomics’ partner, Avistone Biotechnology, received approval from Chinese National Medical Products Administration (NMPA) to commercialize vebreltinib (APL-101) in China Compelling clinical data serving as basis of this approval support... Full story

Yahoo Finance • 2 years ago

Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation

FOSTER CITY, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant can... Full story

Yahoo Finance • 2 years ago

Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion

FOSTER CITY, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced a report by the Veneto Institute of Oncology on the efficacy response of a patient treated with vebreltinib for GBM wi... Full story

Yahoo Finance • 2 years ago

Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%

FOSTER CITY, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), today announced the presentation of vebreltinib efficacy and safety data from the KUNPENG clinical trial at the European Society of Me... Full story

Yahoo Finance • 2 years ago

Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

FOSTER CITY, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatme... Full story

Yahoo Finance • 2 years ago

Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update

Phase2datafromvebreltinib(APL-101),ahighlyselectivecMetinhibitor,inpatientswithNSCLCwith MET exon14 skipping mutation expected second half 2023 Approximately$52.6millionincash,cashequivalents,andinvestmentsatJune30,2023;Cashrunwayto mid-y... Full story